| First Author | Nielsen TO | Year | 2015 |
| Journal | Cancer Discov | Volume | 5 |
| Issue | 2 | Pages | 124-34 |
| PubMed ID | 25614489 | Mgi Jnum | J:221973 |
| Mgi Id | MGI:5643810 | Doi | 10.1158/2159-8290.CD-14-1246 |
| Citation | Nielsen TO, et al. (2015) Synovial sarcoma: recent discoveries as a roadmap to new avenues for therapy. Cancer Discov 5(2):124-34 |
| abstractText | Oncogenesis in synovial sarcoma is driven by the chromosomal translocation t(X,18; p11,q11), which generates an in-frame fusion of the SWI/SNF subunit SS18 to the C-terminal repression domains of SSX1 or SSX2. Proteomic studies have identified an integral role of SS18-SSX in the SWI/SNF complex, and provide new evidence for mistargeting of polycomb repression in synovial sarcoma. Two recent in vivo studies are highlighted, providing additional support for the importance of WNT signaling in synovial sarcoma: One used a conditional mouse model in which knockout of beta-catenin prevents tumor formation, and the other used a small-molecule inhibitor of beta-catenin in xenograft models. SIGNIFICANCE: Synovial sarcoma appears to arise from still poorly characterized immature mesenchymal progenitor cells through the action of its primary oncogenic driver, the SS18-SSX fusion gene, which encodes a multifaceted disruptor of epigenetic control. The effects of SS18-SSX on polycomb-mediated gene repression and SWI/SNF chromatin remodeling have recently come into focus and may offer new insights into the basic function of these processes. A central role for deregulation of WNT-beta-catenin signaling in synovial sarcoma has also been strengthened by recent in vivo studies. These new insights into the the biology of synovial sarcoma are guiding novel preclinical and clinical studies in this aggressive cancer. |
